Takeda Reports Results of TAK-003 in P-III TIDES (DEN-301) Trial for Dengue
Shots:
- The P-III TIDES study contains three parts assessing TAK-003 (0.5ml- SC) vs PBO in patients for the prevention of dengue fever of any severity and due to any of the four dengue virus serotypes in children and adolescents- evaluating the efficacy- safety and immunogenicity
- The P-III study demonstrated well-tolerated- safe and efficacious results in preventing fever till date and is being continued with expected results in H2’19
- Takeda’ TAK-003 is a tetravalent live-attenuated dengue serotype 2 virus and has shown safe and well-tolerated results in P-I/II study for children and adolescent
Ref: Takeda| Image: Takeda
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com